Product Overview
Retatrutide is the furthest-reaching of the incretin experiments. Where earlier molecules imitate one hormone, this one copies three: GIP, GLP-1 and glucagon. The third receptor is the interesting part, because glucagon signalling raises energy expenditure while the other two suppress how much food is eaten, and that pairing is the reason the compound is still followed so closely after the first reports.
Generic Peptides ships it as 5 mg, 10 mg and 20 mg lyophilised vials. Nothing in the range corresponds to a licensed strength, because there is no licence: the molecule remains investigational, holds no approved label, and has no trade name of its own in these packs. Its development code, LY3437943, appears in the literature instead.
There is a gap worth stating in plain words. Reviews and vendor material describe a once-weekly injection, yet a human elimination half-life has not been published in the sources checked here. The weekly rhythm therefore rests on how the trials were run rather than on a measured figure, which matters when a user tries to predict how long an effect will linger. For doping control the whole GLP-1 group stays off the prohibited list while sitting on the monitoring programme, and there is no established laboratory window for a peptide form. Tirzepatide shows how the two-receptor version differs.
Dosage Protocol
Every figure in this table is experimental. Phase 2 used 4 mg and 8 mg maintenance bands after a slow build-up, phase 3 planned 9 mg and 12 mg, and no regulator has signed off on any of them. A separate female arm was not reported.
| Stage | Amount | Length | Note |
| Opening band | Low starting step, built up slowly | At least 4 weeks | Tolerability was better when the first step was 2 mg rather than 4 mg |
| Middle band | 4 mg or 8 mg studied | 24-48 weeks | Group averages in phase 2 came from these two bands |
| Upper band | 9 mg and 12 mg (phase 3 design) | 80-104 weeks | Still no approved amount on any label |
| Female | No separate protocol reported | - | Sources checked list none |
| Route | Subcutaneous | Weekly | Research convention rather than a proved interval |
Dilution decides how fine the steps can be. At 1 ml of bacteriostatic water the 5 mg vial holds 5 mg per millilitre, the 10 mg vial doubles that, and the 20 mg vial reaches 20 mg per millilitre, which is too concentrated for small adjustments. Adding 2 ml halves each figure in turn, and a 20 mg vial mixed with 4 ml behaves like four 5 mg vials. Anything below about 1 mg drawn from a concentrated barrel is hard to measure accurately, so a weaker mix is the practical choice.
Suggested Protocols
This molecule is studied alone. The shelf around it holds single-pathway fat agents and growth-hormone peptides, and comparing routes is more useful than pretending they stack.
The rest of the fat-loss shelf reads as context rather than as partners: Adipotide for the vascular-targeting idea, Tesamorelin where visceral fat is measured, Somatropin for growth-hormone-driven body composition, and NAD+ for cellular energy work. Course length follows the trials: 24 to 48 weeks in phase 2, 80 weeks and beyond in phase 3, with no short-cycle tradition at all.
What to Expect
- Hunger falls early. Appetite changes are usually noticed within the opening weeks, while the scale needs months to move.
- Weight comes off in a curve, not a step. Phase 2 at 48 weeks produced group averages spanning 8.7 to 24.2 percent, with the biggest losses in the upper bands.
- Digestive upset tracks every increase. Nausea, diarrhoea and vomiting cluster on the weeks when the amount goes up and ease when the pace is left slow.
- Pulse drifts upward at first. A small rise in resting heart rate peaked around week 24 in the reported data and then came down.
- Phase 3 was large. TRIUMPH-1 ran 80 weeks in 2339 adults and reported how many left the obesity category, but the product remains unapproved.
- Nobody has published withdrawal data. No discontinuation study for this molecule was found, so the size of any rebound is genuinely unknown.
- Mixing and sterility are the user's problem. A research vial carries no pharmacy oversight.
Side Effects and Management
The profile resembles the rest of the incretin family, with a digestive core and a cardiovascular tail. Reviewing the dose step before adding anything else solves most of it.
Post-Cycle Therapy (Not Required)
There is no hormonal shutdown to reverse. Retatrutide leaves the gonadal axis alone, so tamoxifen, clomiphene and hCG have no role in ending a course, and the sources describe nothing of the kind.
Store the powder cold and away from light. Once mixed, the solution belongs in a refrigerator, never a freezer, and the precise shelf life for these particular vials has not been confirmed by the vendor.
